Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 1671-1680 of 9365

Page
per page
  1. SBE 13 HCl
    B5857 SBE 13 HCl
    Target: PLK
    Summary: Inactive Plk1 inhibitor
      Soluble in DMSO
  2. ITD 1
    B5858 ITD 1
    Summary: The first selective TGFβ inhibitor
      ≥28.05 mg/mL
  3. Entrectinib
    B5859 Entrectinib
    Target: Trk Receptors|ALK|ROS1
    Summary: Orally active inhibitor of ALK kinase
      ≥28.05 mg/mL
  4. TAK960
    B5860 TAK960
    Target: PLK
    Summary: Oral and selective PLK1 inhibitor
      ≥28.05 mg/mL
  5. Molidustat (BAY85-3934)
    B5861 Molidustat (BAY85-3934)
    Target: HIF-PH
    Summary: Novel HIF-PH inhibitor
  6. LX7101 HCL
    B5863 LX7101 HCL
    Summary: Dual LIM-kinase and ROCK inhibitor
      insoluble in H2O; insoluble in EtOH; insoluble in DMSO
  7. Fruquintinib(HMPL-013)
    B5864 Fruquintinib(HMPL-013)
    Target: VEGFR
    Summary: Potent and selective inhibitor of VEGFR 1, 2, 3
      insoluble in H2O; insoluble in EtOH; ≥6.35 mg/mL
  8. MK3102
    B5868 MK3102
    Summary: Novel long-acting DPP-4 inhibitor
      insoluble in EtOH; insoluble in H2O; ≥17.15 mg/mL
  9. ELR510444
    B5870 ELR510444
    Summary: Novel microtubule disruptor
      insoluble in H2O; insoluble in EtOH; ≥11.9 mg/mL
  10. RQ-00203078
    B5872 RQ-00203078
    Summary: Selective and orally active TRPM8 antagonist
      insoluble in H2O; ≥18.85 mg/mL

Items 1671-1680 of 9365

Page
per page